The short version of amino acid sequence fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-09-02 and is reviewed periodically as new material appears.
Terminology in the literature is not fully standardised. Papers and product listings use BPC-157, BPC 157, and the longer phrase stable gastric pentadecapeptide BPC 157 interchangeably, and synonyms such as bepecin or PL 14736 appear in older or company-linked publications. Purity claims and reported masses can also differ between sources because peptide preparations may include counterions, residual solvents, or bound water. This variability complicates direct comparison of results across studies and makes the exact identity and grade of a given sample worth verifying. Discussions of the compound should therefore specify the source, salt form, and stated purity where those are known.
BPC-157 is a synthetic peptide composed of fifteen amino acid residues, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its name derives from body protection compound, a term used for a protein fraction identified in human gastric juice. Researchers in Zagreb first reported the pentadecapeptide in the early 1990s and described it as a stable fragment of that larger protein. The compound is also catalogued as PL 14736 and, in some commercial contexts, as bepecin. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
BPC-157 is a synthetic peptide of fifteen amino acids, written as GEPPPGKPADDAGLV, whose sequence matches part of a larger protein identified in human gastric juice. That parent protein was described in stomach-secretion research, and the fifteen-residue fragment was named body protection compound, which gives the peptide its common label. Material used in experiments is produced by solid-phase peptide synthesis rather than extracted from tissue. The reported molecular weight is about 1419 daltons, and the chain contains several proline residues, a feature that appears in discussions of its resistance to enzymatic breakdown.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C62H98N16O22 | Computed for the free peptide |
| Monoisotopic mass | Approximately 1419 Da | Reported values shift with counterion and hydration |
| Residue count | 15 amino acids | Sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val |
| Origin | Fragment of human gastric juice protein | First described in early 1990s research reports |
| Common synonyms | BPC 157; PL 14736; bepecin | Naming varies across papers and catalogues |
Most published work on BPC-157 comes from animal experiments rather than controlled human trials. Rodent models have examined its effects on gastrointestinal lesions, tendon and ligament injury, and blood vessel formation. These studies are often small and originate from a limited number of research groups, which affects how broadly the findings can be generalized. No large randomized human trial has been reported in the peer-reviewed literature. Discussion of the compound therefore rests largely on preclinical data, and questions about its effects in people remain open rather than settled.
Several mechanisms have been proposed to explain the activity observed in animal models. The most frequently cited involve signaling through vascular endothelial growth factor receptor 2 and modulation of the nitric oxide system. Researchers have also described interactions with protective pathways in the gut lining. These proposed mechanisms appear in the literature as hypotheses supported by preclinical observations, not as confirmed pathways in humans. The precise way the peptide produces its reported effects, and whether those effects carry across species, remain areas of active and unresolved investigation.
BPC-157 is a synthetic pentadecapeptide, meaning it consists of fifteen amino acids joined in a single chain. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, a fragment corresponding to part of a larger protein found in human gastric juice. The peptide was first described in the 1990s by researchers in Zagreb who were studying gastric protective factors. It is not a naturally circulating hormone; it is a laboratory-made fragment derived from a stomach protein. The name is an abbreviation of body protection compound, with the number referring to the fragment's position in the source protein.
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence is GEPPPGKPADDAGLV. Its name derives from the phrase body protection compound, a term applied to a protein fraction originally detected in human gastric juice. The short peptide is not that full protein; it corresponds to a stable fragment of the larger molecule. Researchers frequently describe it as a pentadecapeptide because it contains exactly fifteen residues. Its neutral molecular mass is approximately 1419 daltons.
The sequence places several glycine and proline residues near the middle, which may influence how the chain folds in solution. The peptide is linear rather than cyclic, and it carries no disulfide bridges. Commercial material is commonly supplied as the acetate salt, although the free base and other counterion forms also appear. Because the term BPC-157 refers to a specific sequence, samples with slight sequence variants are chemically different substances. Published work generally treats the fifteen-residue sequence as the defining structure.
BPC-157 is a synthetic pentadecapeptide whose sequence is commonly given as Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is described in the literature as a fragment of a larger protein found in human gastric juice, referred to as body protection compound. The peptide was first characterized in the early 1990s by a research group in Zagreb, Croatia. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Supplied material is typically a lyophilized white to off-white powder. The peptide is freely soluble in water and in common aqueous buffers, which allows it to be handled as a stock solution. Because the sequence contains no cysteine, disulfide cross-linking is not a route of degradation. The absence of aromatic residues means ultraviolet absorbance at 280 nm is minimal, so quantification usually relies on peptide bond absorbance near 214 nm or on amino acid analysis.
Common synonyms in catalogs include pentadecapeptide BPC 157, BPC157, and the full sequence name. A CAS registry number in the 137525-51-0 range is frequently listed, though the assignment should be verified against the supplier certificate of analysis. The name itself is not a pharmacopoeial designation, and there is no standardized international nonproprietary name. Distinguishing genuine material from related fragments generally requires mass spectrometry, since several truncated sequences share similar chromatographic behavior.
BPC-157 is a synthetic peptide built from fifteen amino acid residues. Its sequence comes from a larger protein fragment that researchers isolated from human gastric juice and described as a body protection compound. The fragment contains glycine, glutamic acid, five prolines, lysine, alanine, two aspartic acids, leucine, and valine. The number 157 in the name refers to the position of the stretch within the parent protein. Material used in laboratories is manufactured rather than extracted from stomach fluid.
The molecule carries 15 residues, a molar mass near 1419.5 g/mol, and the formula C62H98N16O22. Its structure features a proline-rich central region, a pair of adjacent aspartic acid residues, and no cysteine. The absence of cysteine means no disulfide bonds can form, which simplifies refolding and reconstitution. Suppliers usually ship the material as a freeze-dried powder that appears white to off-white. It dissolves readily in water and in saline solutions.
Meso-zeaxanthin, lutein, and 3R,3′R-zeaxanthin are the main carotenoids in the macula lutea, found in a ratio of 1:1:1, and are collectively referred to as macular pigment (MP). Meso-zeaxanthin is concentrated at the epicentre of the macula, where it accounts for around 50% of MP at this location, with lutein dominating the peripheral macula.
Space manufacturing or In-space manufacturing (ISM in short) is the fabrication, assembly or integration of tangible goods beyond Earth's atmosphere (or more generally, outside a planetary atmosphere), involving the transformation of raw or recycled materials into components, products, or infrastructure in space, where the manufacturing process is executed either by humans or automated systems by taking advantage of the unique characteristics of space. Synonyms of Space/In-space manufacturing are In-orbit manufacturing (since most production capabilities are limited to low Earth orbit), Off-Earth manufacturing, Space-based manufacturing, Orbital manufacturing, In-situ manufacturing, In-space fabrication, In-space production, etc. In-space manufacturing is a part of the broader activity of in-space servicing, assembly and manufacturing (ISAM) and is related to in situ resource utilization (ISRU). Three major domains of In-space manufacturing are ISM for space (space-for-space) where products remain in space, ISM for Earth (space-for-Earth) where goods with improved properties produced in outer-space microgravity are transported back to Earth, and ISM for surface where goods are produced on or sent to surfaces of celestial bodies like the Moon, Mars, and asteroids.
A TTP insurgent was killed in a military operation in North Waziristan while a woman was injured in a grenade attack in South Waziristan. Mullah Khel tribesmen repelled militants infiltrating into the village of Maulana Zeenatullah Badan in Orakzai District. A quadcopter attack in South Waziristan killed three civilians and wounded four, two more were injured in a separate quadcopter attack there while three were injured in a quadcopter attack in Bannu District. Pakistan initiated "Operation Shaban" in Balochistan. On 6 July, clashes between Pakistani and Afghan forces continued in Khyber District while nine dead bodies of tribesmen were recovered from Quetta District following a strike by 30-40 TTP insurgents on a meeting of what they claimed to be military collaborators. On 7 July, TTP militants attacked a police post in Ziarat District killing nine Policemen including two SHOs whereas 15 militants were killed in retaliatory clearance operations, several policemen were also captured by the TTP of which eighteen were later executed. CPEC brigde in Bannu District was destroyed by insurgents. An ATF personnel was killed in a skirmish with TTP in Quetta. A quadcopter strike in Bannu District killed one civilian and wounded four others. TTP captured a Pakistani joint post in Harnai District seizing weapons, equipment and vehicles.
== Treatment == The options for kidney replacement therapy are severely limited in cats, as kidney transplants and hemodialysis in veterinary medicine are only carried out in exceptional cases due to the high equipment, logistical and financial costs involved. The aim is therefore to detect chronic kidney disease at the earliest possible stage, when the kidneys still have sufficient reserve capacity. At the same time, attempts are made to reduce the amount of urinary substances—especially nitrogen compounds and phosphate—in the diet by means of dietary measures. Finally, metabolic imbalances and sequelae must be buffered. From a plasma creatinine level of 7 mg/dL (618.8 μmol/L), however, drug therapy is not very promising.
Acetoxolutamide is a nonsteroidal androgen and selective androgen receptor modulator (SARM) which was described in 2000 and was never developed or marketed for medical use. It was derived from structural modification of the nonsteroidal antiandrogen bicalutamide and the nonsteroidal SARM acetothiolutamide. Acetoxolutamide shows greatly improved pharmacokinetic properties and anabolic and androgenic potency relative to acetothiolutamide in animals. It is the (2R) enantiomer of andarine (also known as acetamidoxolutamide or androxolutamide).
Sources: en.wikipedia.org
== Critical reception == Gordon Freeman quickly became and then remained one of the most popular video game characters ever. In 2008, The Age ranked him as the 16th-best Xbox character of all time, adding that "no one has done more for the reputations and street cred of theoretical physicists than Valve." In 2009, GameDaily listed the "strong and silent type" in their top 25 video game archetypes, using Gordon Freeman as an example. In 2010, Empire ranked him as the number one Greatest Video Game Character, commenting that "the character is the quintessential geek fantasy" who "has become a gaming icon, synonymous with the apotheosis of first-person action." He was also ranked 14th on UGO.com's list of top 100 heroes in all media, with a comment that "an MIT graduate, donning black-framed glasses and a goatee, he's not the guy you'd picture decimating the alien threat." In 2012, GamesRadar ranked him as the sixth "most memorable, influential, and badass" protagonist in games, adding: "It's how the characters of the Half-Life universe treat Gordon Freeman, not the way he treats them, that shape such a compelling character." In 2013, Complex ranked him as the 45th "most badass" video game character of all time. In 1998, readers of GameSpot ranked him as the fifth-best Hero of gaming. In 2009, a public poll on GameSpot resulted in him being voted the All Time Greatest Video Game Hero. He was also voted as the eighth-best video game character of all time in the Guinness World Records Gamer's Edition 2011.
However, in December 2016, the US took steps to reinstate retaliatory tariffs given continued concerns about EU market access, and in August 2019 they agreed to establish an initial duty-free tariff-rate quota of 18,500 tonnes annually, growing in phases over seven years to 35,000 tonnes (valued at approximately US$420 million) of the EU 45,000 tonnes quota of non-hormone treated beef.
=== Youth === East German Junior Championship (de) Winners: 1961, 1971, 1974, 1976, 1977 Runners-up: 1964, 1972, 1982 East German Youth Championship (de) Winners: 1969, 1971, 1979, 1981, 1984 (record) Runners-up: 1966, 1970, 1978, 1980 East German Junior Cup (Junge Welt-Pokal) (de) Winners: 1971, 1974, 1975, 1988 East German Youth Cup (Youth FDGB-Pokal) Winners: 1959, 1968
== Discovery == German chemist Felix Ehrlich discovered isoleucine while studying the composition of beet-sugar molasses 1903. In 1907 Ehrlich carried out further studies on fibrin, egg albumin, gluten, and beef muscle in 1907. These studies verified the natural composition of isoleucine. Ehrlich published his own synthesis of isoleucine in 1908.
Sources: en.wikipedia.org
==== Manufacture ==== C-4 is manufactured by combining the above ingredients with binders dissolved in a solvent. Once the ingredients have been mixed, the solvent is extracted through drying and filtering. The final material is a solid with a dirty white to light brown color, a putty-like texture similar to modeling clay, and a distinct smell of motor oil. Depending on its intended usage and on the manufacturer, there are differences in the composition of C-4. For example, a 1990 U.S. Army technical manual stipulated that Class IV composition C-4 consists of 89.9±1% RDX, 10±1% polyisobutylene, and 0.2±0.02% dye that is itself made up of 90% lead chromate and 10% lamp black. RDX classes A, B, E, and H are all suitable for use in C-4. Classes are measured by granulation. The manufacturing process for Composition C-4 specifies that wet RDX and plastic binder are added in a stainless steel mixing kettle. This is called the aqueous slurry-coating process. The kettle is tumbled to obtain a homogeneous mixture. This mixture is wet and must be dried after transfer to drying trays. Drying with forced air for 16 hours at 50 °C to 60 °C is recommended to eliminate excess moisture. C-4 produced for use by the U.S. military, commercial C-4 (also produced in the United States), and PE-4 from the United Kingdom each have their own unique properties and are not identical. The analytical techniques of time-of-flight secondary ion mass spectrometry and X-ray photoelectron spectroscopy have been demonstrated to discriminate finite differences in different C-4 sources.
That turned into 'maybe we can fucking do this.' And that turned into this." In September 2008, it was announced that Alice in Chains would headline Australia's Soundwave Festival in 2009, alongside Nine Inch Nails and Lamb of God. In February 2009, it was also announced that Alice in Chains would play at the third annual Rock on the Range festival. On August 1, 2009, Alice in Chains performed, along with Mastodon, Avenged Sevenfold, and Glyder, at Marlay Park, Dublin as direct support to Metallica. The band made an appearance on Later... with Jools Holland on November 10, 2009, performing "Lesson Learned", "Black Gives Way to Blue", and "Check My Brain" as the final performance of the episode. To coincide with the band's European tour, Alice in Chains released its next single, "Your Decision", on November 16, 2009, in the UK and on December 1 in the US. The last single from the album was "Lesson Learned", and it was released to rock radio on June 22, 2010. Black Gives Way to Blue debuted at No. 5 on the Billboard 200. On May 18, 2010, the album was certified gold by the RIAA for selling over 500,000 copies in the U.S. The singles "Check My Brain" and "Your Decision" reached No. 1 on Billboard's Mainstream Rock Tracks, while "Lesson Learned" reached No. 4. "Check My Brain" was also the band's first No. 1 song on the Alternative Songs chart, and on the Hot Rock Songs chart, it also reached No. 92 on Billboard's Hot 100, becoming the band's first single to appear on the chart.
==== Defense and national security ==== While spending on defense and security becomes very important to examine when dealing with a country immersed in an armed conflict, the analysis on this issue is relatively recent. This can be explained because until the beginning of the second half of the nineties, defense and security spending had significant growth. Spending on defense and security includes, on one hand, the means by which the State must have to defend sovereignty and territorial integrity, and on the other, the costs involved in maintaining internal security. Various studies of National Planning suggest that the Colombian State spends a much greater percentage in defense and security than other Latin American countries. Between 1991 and 1996, the estimated value of these resources was $3.7 billion. That amounts to 2.6% of Colombia's GDP, while the average of this expentiure in Latin American countries was 1.7% of GDP. A study carried out by the Stockholm International Peace Research Institute (SIPRI) for the year 2001 shows that, "Colombia ranked 24th in the countries with the largest participation in military spending, out of a total of 116 investigated. The figure for the participation of military expenditures in GDP was 3.8% for Colombia, while in the countries of the American continent the closest figure is that of the United States with 3.1%, followed by Chile with 2.9%, Ecuador with 2.1%, and the rest of countries below 2.0% ". Thus, for the period 1999–2003, defense and security spending was $8,463,611.0 million, equivalent to 10.5% of GDP in 2003.
Sources: en.wikipedia.org
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence corresponds to a fragment of a protein found in human gastric juice. It is studied mainly in preclinical research and is not an approved pharmaceutical product in major markets. Materials sold for laboratory use are typically labelled as research chemicals.
No medicines regulator in the United States or the European Union has approved BPC-157 as a therapeutic product. Presenting it as a drug or as a dietary supplement ingredient would generally not match its regulatory status. Availability as a research chemical does not imply clinical approval.
Published reports rest largely on animal models and cell culture rather than controlled human trials. Review articles describe the proposed mechanisms as incompletely understood. Conclusions about effects in humans therefore remain tentative.
It is not approved for human use in the United States or the European Union. Clinical material has been studied in a small number of early trials, mainly for inflammatory bowel conditions, and the compound remains investigational. Regulators treat marketed products as unapproved rather than as authorized drugs.